Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4131-4137

  Matthews, Kellie ^a,i   Noker, Patricia E ^e   Tian, Baohong ^e   Grimes, Sheila D ^e   Fulton, Ronna ^e   Schweikart, Karen ^f   Harris, Raymond ^g   Aurigemma, Rose ^g   Wang, Minghui ^c   Barnes, Mack N ^a   Siegal, Gene P ^d   Hemminki, Akseli ^h   Zinn, Kurt ^b   Curiel, David T ^c   Alvarez, Ronald D ^a  

^a University of Alabama   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f Clinical Pharmacology Branch   (United States)

^g SAIC FREDERICK INC   (United States)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR 5 SSTR TK RGD; ARGINYLGLYCYLASPARTIC ACID; GANCICLOVIR; SOMATOSTATIN RECEPTOR 5; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SAFETY; FEMALE; INFLAMMATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SUICIDE GENE; SYRIAN HAMSTER; TK GENE; VIRUS INFECTIVITY;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CRICETINAE; FEMALE; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MESOCRICETUS; RECEPTORS, SOMATOSTATIN;

EID: 67449132350     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3354     Document Type: Article

References (32)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529 (Pubitemid 39603165)
2. Barnes M, Deshane J, Rosenfeld M, Siegal G, Curiel D, Alvarez R. Gene therapy and ovarian cancer : a review. Obstet Gynecol 1997;89:145-155 (Pubitemid 27024487)
3. Kanerva A, Raki M, Hemminnki A. Gene therapy of gynaecological diseases. Expert Opin Biol Ther 2007;7:1347-1361 (Pubitemid 47485148)
4. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res 2001;61:813-817 (Pubitemid 32174383)
5. Raki M, Rein DT, Kanerva A, Hemminki A. Gene transfer approaches for gynecological diseases. Mol Ther 2006;14:154-163 (Pubitemid 43942349)
6. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor- independent cell entry mechanism. Virology 1999;72:9706-9713 (Pubitemid 28520834)
7. Krasnykh V, Dmitriev I, Navarro JG, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 2000;60:6784-6787 (Pubitemid 32059138)
8. Vanderkwaak T, Wang M, Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999;74:227-234 (Pubitemid 29377217)
9. Blackwell J, Li H, Navarro J, et al. Circumventing inhibitory factors in ascites fluid using a tropism-modified adenoviral vector. Hum Gene Ther 2000;11:1657-1669
10. Shah K. Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol Ther 2005;4:518-523 (Pubitemid 41351223)
11. Raty JK, Liimatainen T, Unelma Kaikkonen M, Grohn O, Airenne KJ, Yia-Hertual S. Non-invasive imaging in gene therapy. Mol Ther 2007;15:1579-1586 (Pubitemid 47289000)
12. Zinn K, Buchsbaum D, Chaudhuri T, Mountz J, Grizzle W, Rogers B. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high affinity peptide radiolabeled with 99mTc or 188Re. JNucl Med 2000;41:887-895 (Pubitemid 30266035)
13. Belousova N, Harris R, Zinn K, et al. Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Mol Pharmacol 2006;70:1488-1493 (Pubitemid 44776408)
14. Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-1276 (Pubitemid 43259903)
15. Freeman S, Whartenby K, Koeplin D. Tumor regression when a fraction of the tumor cells contain the HSV-TK gene. J Cell Biochem1992;16:45-48
16. Rosenfeld M, Feng M, Michael S, Siegal G, Alvarez R, Curiel D. Adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1995;1:1571-1580 (Pubitemid 26030986)
17. Rosenfeld M, Wang M, Siegal G, et al. Adenoviral mediated delivery of herpes simplex thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996;74:455-462 (Pubitemid 26261899)
18. Alvarez R, Navarro J, Wang M, et al. Adenoviral mediated suicide gene therapy for ovarian cancer. Mol Ther 2000;2:524-530
19. Robinson W, Adams J, Marrogi A, Freeman S. Vaccine therapy for ovarian cancer using herpes simplex virus thymidine kinase (HSV-TK) suicide gene transfer technique: a phase I study [abstract]. Gynecol Oncol 1998;68:88.
20. Link C, Eldeman M, Tennant L, Levy J, Moorman D, Seregina T. LTKOSN.1 murine vector producer cell (VPC) for the in vivo delivery of the herpes simplex thymidine kinase (HSV-TK) gene for ovarian cancer [abstr. 915]. Am Soc Gene Ther 1999.
21. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000;7:839-844 (Pubitemid 30437283)
22. Hasenburg A, Tong XW, Fischer DC, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 2001;83:549-554 (Pubitemid 33139718)
23. Hasenburg A, Fischer DC, Tong XW, et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer 2002;12:66-73. (Pubitemid 34202952)
24. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-2205 (Pubitemid 30826394)
25. Immonen A, Vapalahti M, Tyynelä K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10:967-972 (Pubitemid 39419922)
26. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007;13:5847-5854 (Pubitemid 47583910)
27. Hemminki A, Belousova N, Zinn K, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223-231 (Pubitemid 32851286)
28. Hemminki A, Zinn K, Liu B, et al. In vivo molecular chemotherapy and non-invasive imaging with an infectivity enhanced adenovirus. J Natl Cancer Inst 2002;94:741-749
29. Belousova N, Harris R, Zinn K, et al. Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Mol Pharmacol 2006;70:1488-1493 (Pubitemid 44776408)
30. Thomas RD, Roy D. Base sequence-specific attack of stilbene estrogen metabolite(s) on the mitochondrial DNA: implications in the induction of instability in the mitochondrial genome in the kidney of Syrian hamsters. Int J Mol Med 2001;7:389-395
31. Kimball KJ, Numnum MT, Barnes MN, et al. A phase I study of a tropism modified conditionally replicative adenovirus (CRAd) for recurrent ovarian cancer [abstract]. Mol Ther 2008;16:S113.
32. Page JG, Tian B, Schweikart K, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5- 24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007;196:389e1-10 (Pubitemid 46497925)